JCS Medical, Change of Major Shareholder
JCS Medical announced on the 10th that its largest shareholder is scheduled to change to Syracuse Subco.
Syracuse Subco is a corporation newly established in Korea by Archimed in April, and it announced that from this day until the 22nd of next month, it will conduct a tender offer to purchase 55,724,838 common shares of JCS Medical at 13,000 KRW per share. This corresponds to 72.0% of the total potential issued shares of JCS Medical.
The total amount is approximately 724.4 billion KRW, and NH Investment & Securities is the lead manager for the tender offer.
Hot Picks Today
Per-Capita Burden to Surge to 6.73 Million Won ... "Even Full Salary Isn't Enough for Interest Payments," Lament Overleveraged Borrowers
- Missing Out on a 60 Trillion Won Deal and Suffering a 20% Stock Plunge, But..."Buy While It's Cheap, Hanwha Ocean Has a Rebound Opportunity" [Click e-Stock]
- "Will I Really Be Left Out If I Don't Use It?"... The App Used by 23 Million Koreans Monthly, Is Naver Feeling the Pressure?
- Blue House: Ambassador Kyungwha Kang's Return Aimed at Hearing Views on Developing South Korea-U.S. Relations
- ‘Paradise Island’ Turns into ‘Hell’...4,000 U.S. Soldiers Endure Heat With Only Fans
Archimed is a France-based private equity fund management company established in 2014, primarily investing in the healthcare sector including bio-pharmaceuticals, medical technology, and in vitro diagnostics.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
![[Briefing] National Growth Fund to Expand to 200 Trillion Won... New 'Ultra-Long-Term Technology Investment Fund' with 10-Year Patient Capital Introduced](https://cwcontent.asiae.co.kr/asiaresize/307/2026071511225546911_1784082175.jpg)